Teleflex to Present Innovative Interventional Access Technologies at the Annual Meeting & Postgraduate Course of the Cardiova...
September 09 2016 - 6:45AM
Business Wire
Teleflex Incorporated (NYSE: TFX) a leading global provider of
medical devices for critical care, urology and surgery will
showcase two of its advanced Arrow® Interventional Access Products
at the Annual Congress of the Cardiovascular and Interventional
Radiological Society of Europe (CIRSE) in Barcelona.
During the event, Teleflex will highlight both the Arrow®
OnControl® Powered Bone Access System and the ARROW-Clark™
VectorFlow™ Chronic Hemodialysis Catheter, together with other
technologically advanced products for interventional
applications.
The Arrow® OnControl® Powered Bone Access System offers the
ability to effectively1, safely and rapidly2 obtain high quality
bone samples. Our bone lesion biopsy needle is designed
specifically for multiple bone biopsies from a single cortical
penetration. Using Teleflex’s patented handheld driver technology,
the Arrow® OnControl® Powered Bone Access System provides
interventional radiologists a fast reliable3 solution for accessing
dense and hard-to-reach bone lesions.
The ARROW-Clark™ VectorFlow™ Catheter is the only catheter with
an innovative tip designed to produce a helical, three-dimensional
transition of blood entering and leaving the catheter.4 Designed
for optimum performance, the ARROW-Clark™ VectorFlow™ Catheter
(available in both retrograde and antegrade insertion platforms) is
a tunneled hemodialysis catheter with symmetrical tip that is
designed to reduce loss of lock solution (a contributing factor in
reducing the risk of thrombus adherence), gives sustained high
flows, minimizes recirculation and reduces the risk of platelet
damage resulting from shear stress.5
During the CIRSE Congress on Sunday, September 11 and Monday,
September 12, at 14:00 Prof. Dr. med. Roman Fischbach, Head of
Radiology and Neuroradiology at Asklepios Klinik Altona, will lead
in-booth sessions entitled "CT guided bone biopsy with the Arrow®
OnControl® Powered Bone Access System. Clinical applications,
technique and results."
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people’s lives. We apply
purpose driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference. For more information,
please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rüsch® and Weck® – trusted brands united by a common
sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, ARROW-Clark, Deknatel,
Hudson RCI, LMA, OnControl, Pilling, Rüsch, VectorFlow and Weck are
trademarks or registered trademarks of Teleflex Incorporated or its
affiliates, in the U.S. and/or other countries. © 2016 Teleflex
Incorporated. All rights reserved.
References:
1. Miller LJ, Philbeck TE, Montez DF, et al. Powered bone marrow
biopsy procedures produce larger core specimens, with less pain, in
less time than with standard manual devices. Hematology Reports
2011;3(e8):22-5. doi:10.4081/hr.2011.e8.* Available at: [PMC free
article] [PubMed] verified March 2015.
2. Lee RK, Ng AW, Griffith JF. CT-guided bone biopsy with a
battery-powered drill system: preliminary results. AJR Am J
Roentgenol 2013;201(5):1093-5. doi:10.2214/AJR.12.10521. Available
at: [PubMed] verified March 2015.
3. Miller LJ, Philbeck TE, Montez DF, et al. Powered bone marrow
biopsy procedures produce larger core specimens, with less pain, in
less time than with standard manual devices. Hematology Reports
2011;3(e8):22-5. doi:10.4081/hr.2011.e8.* Available at: [PMC free
article] [PubMed] verified March 2015.
4. Clark T, et al. Computational Flow Dynamics and Preclinical
Assessment of a Novel Hemodialysis Catheter. Seminars in Dialysis
2012;25(5):574-581. doi: 10.1111/j.1525-139X.2012.01052.*
5. Clark TWI, Isu G, Gallo D, Verdonck P, Morbiducci U.
Comparison of symmetric hemodialysis catheters using computational
fluid dynamics. Journal of Vascular and Interventional Radiology.
2015;26(2):252-259. doi: 10.1016/j.jvir.2014.11.004
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160909005038/en/
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor Relations610-948-2836orMartina Teichmann-ZindlerDirector
Marketing Communications International+49
(0)7151-406-538martina.teichmann@teleflex.com
Teleflex (NYSE:TFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Sep 2023 to Sep 2024